Kidney Disease News and Research

RSS

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Amgen Inc. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has announced a positive opinion for the marketing authorization of Prolia((TM)) (denosumab) for the treatment of osteoporosis in postmenopausal women at increased risk of fractures, and for the treatment of bone loss associated with hormone ablation in men with prostate cancer at increased risk of fractures.

18 Dec 2009

Ambulatory monitoring technique can disturb sleep and raise nighttime blood pressure

A widely used test for measuring nighttime blood pressure may interfere with patients' sleep, thus affecting the results of the test, reports a study in an upcoming issue of Clinical Journal of the American Society of Nephrology (CJASN).

18 Dec 2009

Acute kidney injury associated with increased long-term mortality

Patients with sudden loss of kidney function, called acute kidney injury (AKI), are more likely to die prematurely after leaving the hospital—even if their kidney function has apparently recovered, according to an upcoming study inJournal of the American Society of Nephrology (JASN).

18 Dec 2009

Researchers identify genetic markers to help treat chronic kidney disease among diabetics

Researchers using a DNA analysis tool developed by the Translational Genomics Research Institute (TGen) and UCLA have identified genetic markers that could help treat chronic kidney disease among diabetics.

17 Dec 2009

Researchers develop new electrophoretic method for detecting MIRCERA and EPO in blood

Austrian researchers have successfully developed a new electrophoretic method for detecting MIRCERA® and other erythropoietins (EPO) in the blood. The technique, using SARCOSYL-PAGE, has specifically enhanced sensitivity for MIRCERA, but does not alter the performance characteristics of SDS-PAGE for detecting other EPOs.

16 Dec 2009

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Gilead Sciences, Inc. today announced that DAR-312 (DORADO-AC), a Phase III clinical trial evaluating darusentan, the company’s endothelin receptor antagonist (ERA) for the treatment of resistant hypertension, did not achieve its co-primary efficacy endpoints of change from baseline to week 14 in trough sitting systolic blood pressure (SBP) and diastolic blood pressure (DBP) compared to placebo.

15 Dec 2009

Majority of dialysis patients face readmission to acute care facilities, says study

A new study by University of Cincinnati (UC) nephrologists shows that most dialysis patients admitted to long-term care hospitals face readmission to acute care facilities, and those with acute kidney failure don't often recover full kidney function.

15 Dec 2009

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

Researchers at the Los Angeles Biomedical Research Institute (LA BioMed) expect to receive more than $4.5 million in grants from the American Recovery and Reinvestment Act (Recovery Act.), including nearly $1 million from the highly competitive Challenge Grant program for a study that seeks to reduce the number of children who die from Sudden Infant Death Syndrome, it was announced today.

15 Dec 2009

By understanding how gene works, scientists may find ways to prevent, cure diabetes

A gene commonly studied by cancer researchers has been linked to the metabolic inflammation that leads to diabetes.

12 Dec 2009

Carotid endarterectomy can benefit patients with chronic kidney disease

Physicians should be comfortable referring some patients with chronic kidney disease (CKD) for effective stroke prevention surgery, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN). The findings indicate that CKD patients gain a significant benefit from the procedures without an increased risk of dying from surgical complications.

11 Dec 2009

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

Acceleron Pharma, Inc., a biopharmaceutical company developing novel therapeutics that modulate the growth of cells and tissues including red blood cells, bone, muscle, fat, and the vasculature, presented data demonstrating that ACE-536 promotes formation of red blood cells through inhibition of members of the TGF-beta superfamily, at the 51st Annual Meeting of the American Society of Hematology.

8 Dec 2009

People infected with West Nile virus may have persistent virus in their kidneys, shows study

A new study shows that people who have been infected with West Nile virus may have persistent virus in their kidneys for years after initial infection, potentially leading to kidney problems.

8 Dec 2009

Amgen announces results from first Phase 1/2 study of Nplate

Amgen Inc. today announced results from its first Phase 1/2 study evaluating the safety and efficacy of Nplate® (romiplostim) in children with chronic immune thrombocytopenic purpura (ITP).

8 Dec 2009

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

Alexion Pharmaceuticals, Inc. today announced positive data from the 26-week extension of the AEGIS study, an open-label registration study examining Soliris® (eculizumab) for the treatment of Japanese patients with paroxysmal nocturnal hemoglobinuria (PNH).

7 Dec 2009

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

Alexion Pharmaceuticals, Inc. today announced presentation of data showing that the presence of Type II paroxysmal nocturnal hemoglobinuria (PNH) cells is correlated with thrombocytopenia, potentially indicating that patients with Type II cells experience ongoing platelet consumption and increased thrombosis risk.

7 Dec 2009

Amgen announces results from three studies on the safety and efficacy of Nplate

Amgen Inc. today announced results from three studies on the safety and efficacy of Nplate® (romiplostim) in adult patients with myelodysplastic syndromes (MDS).

7 Dec 2009

Norovirus-related illnesses linked to eating oysters, reveals report

The U.S. Food and Drug Administration is advising consumers to avoid eating oysters harvested from the San Antonio Bay on or after Nov. 16 due to reports of norovirus-associated illnesses in some people who had consumed oysters harvested from this area, which is located on the Gulf of Texas.

7 Dec 2009

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

Genzyme Corporation announced today that it will reopen enrollment in the Alglucosidase Alfa Temporary Access Program (ATAP), a program which provides access to treatment for severely affected adults with Pompe disease prior to commercial approval of Lumizyme™ (alglucosidase alfa). Genzyme and the FDA have also agreed on a path toward approval of Lumizyme.

4 Dec 2009

New tool may allow doctors to predict long-term survival rates of dialysis patients

A new model can help physicians determine if a kidney disease patient on dialysis is likely to die within the next few months, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN).

4 Dec 2009

Updated results from MYTHOS clinical trial of RenalGuard presented at AHA meeting

PLC Systems Inc., a company focused on innovative cardiac and vascular medical device-based technologies, today announced that updated results from the MYTHOS investigator-sponsored clinical trial of RenalGuard(®) were presented at the American Heart Association (AHA) Scientific Sessions 2009, on Sunday, November 15 in Orlando, Florida.

2 Dec 2009

Kidney Disease News and Research

European CHMP announces positive opinion for Amgen's Prolia marketing authorization

Ambulatory monitoring technique can disturb sleep and raise nighttime blood pressure

Acute kidney injury associated with increased long-term mortality

Researchers identify genetic markers to help treat chronic kidney disease among diabetics

Researchers develop new electrophoretic method for detecting MIRCERA and EPO in blood

Phase III clinical trial evaluating darusentan misses its co-primary efficacy endpoints

Majority of dialysis patients face readmission to acute care facilities, says study

Researchers to receive more than $4.5 million in grants to study Sudden Infant Death Syndrome

By understanding how gene works, scientists may find ways to prevent, cure diabetes

Carotid endarterectomy can benefit patients with chronic kidney disease

Acceleron Pharma's ACE-536 stimulates red blood cell production through novel mechanism

People infected with West Nile virus may have persistent virus in their kidneys, shows study

Amgen announces results from first Phase 1/2 study of Nplate

Alexion Pharmaceuticals announces positive data from AEGIS study of Soliris

New data shows patients with Type II PNH cells experience platelet consumption and increased thrombosis risk

Amgen announces results from three studies on the safety and efficacy of Nplate

Norovirus-related illnesses linked to eating oysters, reveals report

Genzyme announces reopening of enrollment in its Pompe disease ATAP program

New tool may allow doctors to predict long-term survival rates of dialysis patients

Updated results from MYTHOS clinical trial of RenalGuard presented at AHA meeting

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Latest News